AstraZeneca Makes $10 Billion Offer to Acquire Obesity Drugmaker Rhythm Pharmaceuticals The non-binding bid values the rare obesity drugmaker at up to $134 a share. Credit: GLOBE NEWSWIRE/Rhythm Pharmaceuticals Subscribe now Already have an account? Sign in.
